FDA Approves Ropeginterferon Alfa-2b-Njft for Polycythemia Vera

The FDA has approved ropeginterferon alfa-2b-njft (Besremi®, PharmaEssentia) for patients with polycythemia vera, marking the first approval of interferon therapy specifically for patients with polycythemia vera and the first treatment for all patients with polycythemia vera, regardless of their prior treatment history. "Ropeginterferon alfa-2b is a novel long-acting monopegylated IFN-alpha-2b," wrote Heinz Gisslinger, MD, Professor of Hematology at the Medical University of Vienna, Austria, and...
Continue reading

Morning People Have Lower Breast Cancer Risk

In 2007, the World Health Organization classified shift work that disrupts the circadian rhythm as a potential risk factor for cancer. This increased risk could be due to disturbed sleep, exposure to light at night, and exposure to additional lifestyle factors that correlate with shift work. Plenty of research has been conducted on the adverse effects on breast cancer risk of night shift work and exposure to light at night; however, less research has been done on the possible adverse effects of ...
Continue reading

Can Artificial Intelligence Diagnose Skin Lesions? With Philipp Tschandl, MD, PhD

​Philipp Tschandl, MD, PhD, and colleagues found that current artificial intelligence (AI) algorithms that use "deep learning"—a type of machine learning that is based on artificial neural networks—outperform humans, even experts, in the classification of pigmented skin lesions. In this interview with i3 Health, Philipp Tschandl, member of the Vienna Dermatologic Imaging Research (ViDIR) Group of the Medical University of Vienna's Department of Dermatology, discusses the significance of the stud...
Continue reading

AI Beats Human Experts in Classifying Skin Lesions

A new study reports that artificial intelligence (AI) in the form of machine-learning algorithms outperforms human experts in the diagnosis of pigmented skin lesions. This web-based study, which was published in The Lancet Oncology, included 511 human readers from 63 countries. Of these, 55.4% were board-certified dermatologists, 23.1% were dermatology residents, and 16.2% were general practitioners. The human readers were asked to diagnose dermatoscopic images that had been randomly selected in...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.